These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 19910556)
1. Drug compendia in oncology: are they flawed? Twombly R J Natl Cancer Inst; 2009 Dec; 101(23):1604-6. PubMed ID: 19910556 [No Abstract] [Full Text] [Related]
2. [Oncology--a common language, new perspectives. Lilly Oncology Global Medical Conference, Indianapolis, 1996]. Pneumologie; 1996 Sep; 50(9 Suppl):1-12. PubMed ID: 9022416 [No Abstract] [Full Text] [Related]
3. Gemcitabine in the treatment of bladder cancer. Ryan CW; Vogelzang NJ Expert Opin Pharmacother; 2000 Mar; 1(3):547-53. PubMed ID: 11249537 [TBL] [Abstract][Full Text] [Related]
4. [The role of gemcitabine in the treatment of bladder tumors]. Cortesi E; Gareri R Clin Ter; 1999; 150(1):5-6. PubMed ID: 10367537 [No Abstract] [Full Text] [Related]
5. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. Gontero P; Marini L; Frea B BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511 [No Abstract] [Full Text] [Related]
6. PHARMAC's response on gemcitabine and transparency. Crausaz S; Metcalfe S N Z Med J; 2005 Nov; 118(1225):U1741. PubMed ID: 16286949 [No Abstract] [Full Text] [Related]
7. Chemotherapy for advanced bladder carcinoma: new molecules and regimens. Abi-Aad AS Acta Urol Belg; 1996 May; 64(2):43-5. PubMed ID: 8701810 [No Abstract] [Full Text] [Related]
8. What's happening in PHARMAC--where do all the submissions go? On the trail of gemcitabine. Simpson A N Z Med J; 2005 Nov; 118(1225):U1733. PubMed ID: 16286946 [TBL] [Abstract][Full Text] [Related]
9. [The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.1]. Conti G Arch Ital Urol Androl; 2006 Dec; 78(4 Suppl 1):9-10. PubMed ID: 17491549 [No Abstract] [Full Text] [Related]
10. Systematic review: reliability of compendia methods for off-label oncology indications. Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366 [TBL] [Abstract][Full Text] [Related]
11. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. Roth BJ; Bajorin DF J Urol; 1995 Mar; 153(3 Pt 2):894-900. PubMed ID: 7853569 [No Abstract] [Full Text] [Related]
12. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment]. Beardo Villar P; Gamaza Martínez R; Gavira Moreno R Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of bladder perfusion of alternating hydroxycamptothecin and gemcitabine combined with low-dose tuberculin in the treatment of non-muscle invasive bladder cancer after TURBT. Chen L; Hu W; Li G; Guo Y; Wan Z; Yu J J BUON; 2019; 24(4):1652-1658. PubMed ID: 31646821 [No Abstract] [Full Text] [Related]
14. Gemcitabine in bladder cancer. El Karak F; Flechon A Expert Opin Pharmacother; 2007 Dec; 8(18):3251-6. PubMed ID: 18035967 [TBL] [Abstract][Full Text] [Related]
15. [Elevation of CA 19.9 in urothelial bladder cancer]. Bastos Oreiro M; López Rodríguez M; Monedero Martín MC; Plasencia Rodríguez C Med Clin (Barc); 2008 Mar; 130(8):319. PubMed ID: 18358126 [No Abstract] [Full Text] [Related]